DAVID F. AND MARGARET T. GROHNE FAMILY CANCER IMMUNOLOGY AND IMMUNOTHERAPY PROGRAM PROJECT SUMMARY The Cancer Immunology and Immunotherapy (CII) Program is a longstanding basic and translational sciences program within the Mayo Clinic Cancer Center (MCCC). In 2016, this program was officially endowed by the David F. and Margaret T. Grohne Family. The Program continues to work toward better understanding the mechanisms of immunity, the relationship between inflammation and cancer, and the development of innovative solutions to combat cancer through immune therapy. The CII Program has contributed significantly to checkpoint blockade therapy, which has resulted in a major change in the standard of care of several different cancers. It is now poised to make additional major contributions such as using antibody-targeted chemotherapeutics, effectively targeting melanoma and ovarian cancers, which have proven nonresponsive to established therapies. The Program includes 35 members, representing 14 different departments in the Mayo Clinic College of Medicine and Science. The current membership is a historically highly productive team with a total publication record in excess of 5000 papers that has garnered over 245,000 citations. The main goal of the Program is to provide an interactive, supportive, and durable scientific environment to foster our four principal cutting-edge Specific Aims: (1) To develop new knowledge about how the immune system functions, (2) To develop novel antibody-based therapies for the treatment of cancers (3) To identify and develop vaccine approaches that can be implemented to protect against cancer recurrence and improve the efficacy of immune modulation with checkpoint inhibitors, and (4) To develop innovative strategies to redirect non-tumor antigen- specific T cells to attack cancer. The CII Program has been consistently well-funded and currently is supported by extramural peer-reviewed grants totaling $3.6M in direct costs of which ~35% are from NCI. Direct funding from non-peer-reviewed grants is $8.4M resulting in an overall total of $12M. This is a 20% increase over the last funding period. In the 2013-2017 timeframe, Program members published 650 cancer-related publications, of which 19% were intraprogrammatic, 57% were interprogrammatic, and 124 were published in journals with impact factors ?10, reflecting the quality of the work and illustrating the high degree of interaction the CII Program members have with members of other MCCC Programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications